1,2-dimyristoylphosphatidylethanolamine has been researched along with labetalol in 1 studies
| Studies (1,2-dimyristoylphosphatidylethanolamine) | Trials (1,2-dimyristoylphosphatidylethanolamine) | Recent Studies (post-2010) (1,2-dimyristoylphosphatidylethanolamine) | Studies (labetalol) | Trials (labetalol) | Recent Studies (post-2010) (labetalol) |
|---|---|---|---|---|---|
| 216 | 0 | 59 | 1,980 | 450 | 327 |
| Protein | Taxonomy | 1,2-dimyristoylphosphatidylethanolamine (IC50) | labetalol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 0.016 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.354 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.01 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.393 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.354 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.521 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.393 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 3.037 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.607 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.815 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jemiola-Rzeminska, M; Strzalka, K; Suwalsky, M; Zambrano, P | 1 |
1 other study(ies) available for 1,2-dimyristoylphosphatidylethanolamine and labetalol
| Article | Year |
|---|---|
α1-and β-adrenergic antagonist labetalol induces morphological changes in human erythrocytes.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Calorimetry, Differential Scanning; Dimyristoylphosphatidylcholine; Erythrocyte Membrane; Erythrocytes; Humans; In Vitro Techniques; Labetalol; Liposomes; Membranes, Artificial; Microscopy, Electron, Scanning; Phosphatidylethanolamines; X-Ray Diffraction | 2018 |